Brief: Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026 - SEC Filing
04/03/2026 21:43
March 4 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY INC - APPOINTS MARIANNE DE BACKER AS PRESIDENT IN ADDITION TO CEO ON MARCH 4, 2026 - SEC FILING Source text: [ID:n0001193125-26-091447] Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO